Literature DB >> 33579322

Validation of the 5-domain Niemann-Pick type C Clinical Severity Scale.

Marc C Patterson1, Lucy Lloyd-Price2, Christina Guldberg3, Helen Doll2, Claire Burbridge2, Michael Chladek4, Christine íDali3, Eugen Mengel5, Tara Symonds2.   

Abstract

BACKGROUND: Niemann-Pick disease type C (NPC) is an ultra-rare, progressive, genetic disease leading to impaired lysosomal function and neurodegeneration causing serious morbidity and shortened life expectancy. The Niemann-Pick type C Clinical Severity Scale (NPCCSS) is a 17 domain, disease-specific, clinician-reported outcome measure of disease severity and progression. An abbreviated 5-domain NPCCSS scale has been developed (measuring Ambulation, Swallow, Cognition, Speech, and Fine Motor Skills) and the scale reliability has been established. Additional psychometric properties and meaningful change of the scale need, however, to be assessed.
METHODS: Mixed method studies were conducted to ascertain which NPCCSS domains were most important, as well as to explore meaningful change: 1) surveys in caregivers/patients (n = 49) and 2) interviews with clinicians (n = 5) as well as caregivers/patients (n = 28). Clinical trial data (n = 43) assessed construct validity and meaningful change through an anchor-based approach.
RESULTS: Domains identified as most important by clinicians, caregivers, and patients (independent of current age, age of onset, and disease severity) were Ambulation, Swallow, Cognition, Speech, and Fine Motor Skills, indicating content validity of the 5-domain NPCCSS. Criterion validity was shown with the 5-domain NPCCSS being highly correlated with the 17-item NPCCSS total score (excluding hearing domains), r2 = 0.97. Convergent validity was demonstrated against the 9 Hole Peg Test, r2 = 0.65 (n = 31 patients), and the Scale for Assessment and Rating of Ataxia (SARA), r2 = 0.86 (n = 49 patients). Any change was seen as meaningful by patients/caregivers across domains. Meaningful change using trial data and interviews with NPC experts (n = 5) and patients/caregivers (n = 28) suggested that a 1-category change on a domain is equivalent to 1-point change or greater in the 5-domain NPCCSS total score.
CONCLUSIONS: Qualitative and quantitative data support content and construct validity of the 5-domain NPCCSS score as a valid endpoint in NPC trials. A 1-category change on any domain is equivalent to 1-point change or greater in the 5 domain NPCCSS total score, representing a clinically meaningful transition and reflecting loss of complex function and increased disability. Trial registration NCT02612129. Registered 23 November 2015, https://clinicaltrials.gov/ct2/show/NCT02612129.

Entities:  

Keywords:  Arimoclomol; ClinRO; NPCCSS; Niemann-pick type C clinical severity scale; Validation

Mesh:

Year:  2021        PMID: 33579322      PMCID: PMC7881637          DOI: 10.1186/s13023-021-01719-2

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  15 in total

1.  Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C.

Authors:  Nicole M Yanjanin; Jorge I Vélez; Andrea Gropman; Kelly King; Simona E Bianconi; Sandra K Conley; Carmen C Brewer; Beth Solomon; William J Pavan; Mauricio Arcos-Burgos; Marc C Patterson; Forbes D Porter
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-01-05       Impact factor: 3.568

2.  Scale for the assessment and rating of ataxia: development of a new clinical scale.

Authors:  T Schmitz-Hübsch; S Tezenas du Montcel; L Baliko; J Berciano; S Boesch; C Depondt; P Giunti; C Globas; J Infante; J-S Kang; B Kremer; C Mariotti; B Melegh; M Pandolfo; M Rakowicz; P Ribai; R Rola; L Schöls; S Szymanski; B P van de Warrenburg; A Dürr; T Klockgether; Roberto Fancellu
Journal:  Neurology       Date:  2006-06-13       Impact factor: 9.910

3.  Identification of HE1 as the second gene of Niemann-Pick C disease.

Authors:  S Naureckiene; D E Sleat; H Lackland; A Fensom; M T Vanier; R Wattiaux; M Jadot; P Lobel
Journal:  Science       Date:  2000-12-22       Impact factor: 47.728

Review 4.  The complexity of a monogenic neurodegenerative disease: More than two decades of therapeutic driven research into Niemann-Pick type C disease.

Authors:  Natalie Hammond; Andrew B Munkacsi; Stephen L Sturley
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2019-04-17       Impact factor: 4.698

Review 5.  Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease.

Authors:  Emyr Lloyd-Evans; Frances M Platt
Journal:  Traffic       Date:  2010-01-06       Impact factor: 6.215

Review 6.  Niemann-Pick disease type C.

Authors:  Marie T Vanier
Journal:  Orphanet J Rare Dis       Date:  2010-06-03       Impact factor: 4.123

7.  Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.

Authors:  Daniel S Ory; Elizabeth A Ottinger; Nicole Yanjanin Farhat; Kelly A King; Xuntian Jiang; Lisa Weissfeld; Elizabeth Berry-Kravis; Cristin D Davidson; Simona Bianconi; Lee Ann Keener; Ravichandran Rao; Ariane Soldatos; Rohini Sidhu; Kimberly A Walters; Xin Xu; Audrey Thurm; Beth Solomon; William J Pavan; Bernardus N Machielse; Mark Kao; Steven A Silber; John C McKew; Carmen C Brewer; Charles H Vite; Steven U Walkley; Christopher P Austin; Forbes D Porter
Journal:  Lancet       Date:  2017-08-10       Impact factor: 202.731

Review 8.  Consensus clinical management guidelines for Niemann-Pick disease type C.

Authors:  Tarekegn Geberhiwot; Alessandro Moro; Andrea Dardis; Uma Ramaswami; Sandra Sirrs; Mercedes Pineda Marfa; Marie T Vanier; Mark Walterfang; Shaun Bolton; Charlotte Dawson; Bénédicte Héron; Miriam Stampfer; Jackie Imrie; Christian Hendriksz; Paul Gissen; Ellen Crushell; Maria J Coll; Yann Nadjar; Hans Klünemann; Eugen Mengel; Martin Hrebicek; Simon A Jones; Daniel Ory; Bruno Bembi; Marc Patterson
Journal:  Orphanet J Rare Dis       Date:  2018-04-06       Impact factor: 4.123

9.  Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials.

Authors:  Mario Cortina-Borja; Danielle Te Vruchte; Eugen Mengel; Yasmin Amraoui; Jackie Imrie; Simon A Jones; Christine I Dali; Paul Fineran; Thomas Kirkegaard; Heiko Runz; Robin Lachmann; Tatiana Bremova-Ertl; Michael Strupp; Frances M Platt
Journal:  Orphanet J Rare Dis       Date:  2018-08-16       Impact factor: 4.123

10.  Clinical disease progression and biomarkers in Niemann-Pick disease type C: a prospective cohort study.

Authors:  Eugen Mengel; Bruno Bembi; Mireia Del Toro; Federica Deodato; Matthias Gautschi; Stephanie Grunewald; Sabine Grønborg; Bénédicte Héron; Esther M Maier; Agathe Roubertie; Saikat Santra; Anna Tylki-Szymanska; Simon Day; Tara Symonds; Stacie Hudgens; Marc C Patterson; Christina Guldberg; Linda Ingemann; Nikolaj H T Petersen; Thomas Kirkegaard; Christine Í Dali
Journal:  Orphanet J Rare Dis       Date:  2020-11-23       Impact factor: 4.123

View more
  4 in total

1.  Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment.

Authors:  Eugen Mengel; Marc C Patterson; Rosalia M Da Riol; Mireia Del Toro; Federica Deodato; Matthias Gautschi; Stephanie Grunewald; Sabine Grønborg; Paul Harmatz; Bénédicte Héron; Esther M Maier; Agathe Roubertie; Saikat Santra; Anna Tylki-Szymanska; Simon Day; Anne Katrine Andreasen; Marie Aavang Geist; Nikolaj Havnsøe Torp Petersen; Linda Ingemann; Thomas Hansen; Thomas Blaettler; Thomas Kirkegaard; Christine Í Dali
Journal:  J Inherit Metab Dis       Date:  2021-09-07       Impact factor: 4.750

Review 2.  The Cerebellum in Niemann-Pick C1 Disease: Mouse Versus Man.

Authors:  Maria Teresa Fiorenza; Piergiorgio La Rosa; Sonia Canterini; Robert P Erickson
Journal:  Cerebellum       Date:  2022-01-18       Impact factor: 3.648

3.  Impacts and Burden of Niemann pick Type-C: a patient and caregiver perspective.

Authors:  Eugen Mengel; Marc C Patterson; Michael Chladek; Christina Guldberg; Christine Í Dali; Tara Symonds; Lucy Lloyd-Price; Toni Mathieson; Joslyn Crowe; Claire Burbridge
Journal:  Orphanet J Rare Dis       Date:  2021-11-24       Impact factor: 4.123

4.  Phenotypic expression of swallowing function in Niemann-Pick disease type C1.

Authors:  Beth I Solomon; Andrea M Muñoz; Ninet Sinaii; Nicole M Farhat; Andrew C Smith; Simona Bianconi; An Dang Do; Michael C Backman; Leonza Machielse; Forbes D Porter
Journal:  Orphanet J Rare Dis       Date:  2022-09-05       Impact factor: 4.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.